Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies

被引：23

作者：

Sun, Wanxiao ^{[1
]}

Deng, Yaxin ^{[1
]}

Zhao, Meihui ^{[1
]}

Jiang, Ying ^{[1
]}

Gou, Jingxin ^{[1
]}

Wang, Yanjiao ^{[1
]}

Yin, Tian ^{[2
]}

Zhang, Yu ^{[1
]}

He, Haibing ^{[1
]}

Tang, Xing ^{[1
]}

机构：

[1] Shenyang Pharmaceut Univ, Sch Pharm, Dept Pharmaceut, 103 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China

[2] Shenyang Pharmaceut Univ, Sch Funct Food & Wine, 103 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China

来源：

JOURNAL OF CONTROLLED RELEASE | 2021年 / 333卷

关键词：

Prostate cancer; Nanoparticle; Targeting; Combination therapy; Co-delivery; UROKINASE PLASMINOGEN-ACTIVATOR; AMINO-TERMINAL FRAGMENT; MEMBRANE ANTIGEN PSMA; DRUG-DELIVERY SYSTEM; IN-VITRO; BIODEGRADABLE NANOPARTICLES; SIRNA DELIVERY; BREAST-CANCER; POLYMERIC NANOPARTICLES; LOADED NANOPARTICLES;

D O I：

10.1016/j.jconrel.2021.01.010

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

For the past few years, nanotechnology has provided a lot of new treatment opportunities for prostate cancer patients, and brilliant achievements have been acquired indeed. It not only prolonged circulation time in vivo but also increased bio-availability of drugs. Among them, nanoparticles with specificity ligand can be better targeted at prostate cancer, which improves the curative effect and reduces side effects. What's more, in terms of combined administration, the synergistic effect of chemotherapeutic drugs and hormones, or co-delivery two or more different drugs into the same delivery system, has achieved good therapeutic progress as well. In this paper, a comprehensive overview of nano-technology and the combination therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies have been proposed to further appreciate and recommend the design and development of prostate cancer treatment.

引用

页码：41 / 64

页数：24

共 50 条

[1] Strategies in pharmaceutical care and pharmaceutical public health: quality of cardiovascular drug therapy use
Dreischulte, Tobias
Hudson, Steve A.
[J]. PHARMACY WORLD & SCIENCE, 2009, 31 (02): : 330 - 330
[2] Demographic and Pharmaceutical Predictors of Unfavorable Prostate Cancer
Blacksburg, S. R.
Demircioglu, G.
Carpenter, T. J.
Mirza, A.
Witten, M. R.
Mendez, C.
Katz, A. E.
Haas, J. A.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E265 - E266
[3] Pharmaceutical strategies for endoplasmic reticulum-targeting and their prospects of application
Shi, Yingying
Wang, Sijie
Wu, Jialu
Jin, Xizhi
You, Jian
[J]. JOURNAL OF CONTROLLED RELEASE, 2021, 329 : 337 - 352
[4] Pharmaceutical Targeting of the Brain
Krizbai, Istvan A.
Nyul-Toth, Adam
Bauer, Hans-Christian
Farkas, Attila E.
Traweger, Andreas
Hasko, Janos
Bauer, Hannelore
Wilhelm, Imola
[J]. CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (35) : 5442 - 5462
[5] CLINICAL PHARMACEUTICAL ASPECTS OF LITHIUM-THERAPY
GREENE, RJ
[J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1975, 9 (01): : 17 - 25
[6] Drug development strategies and clinical research in the pharmaceutical industry
Bieber, E
Wingen, FJ
[J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2000, 78 (07): : B36 - B36
[7] A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer
Moussa, Mohamad
Papatsoris, Athanasios
Sryropoulou, Despoina
Chakra, Mohamed Abou
Dellis, Athanasios
Tzelves, Lazaros
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (13) : 1685 - 1728
[8] A Comprehensive Review of Pharmaceutical and Surgical Interventions of Prostate Cancer
Kaler, Jasndeep
Hussain, Azhar
Haque, Ayema
Naveed, Hassan
Patel, Sundip
[J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (11)
[9] Strategies for the pharmaceutical industry
不详
[J]. FUTURIST, 1998, 32 (06) : 64 - 64
[10] STRATEGIES IN PHARMACEUTICAL RESEARCH
JANSSEN, PAJ
[J]. ENDEAVOUR, 1985, 9 (01) : 28 - 33

← 1 2 3 4 5 →